Despite the widespread use of combination antiretroviral therapy (cART), HIV-associated neurocognitive impairment (NCI) remains a health concern. However, limited research has been done to identify factors associated with neurocognitive decline. We assessed risk factors associated with neurocognitive decline in people living with HIV using a definition of decline that is statistically easy to adopt, is based on a commonly used neuropsychological cut-off and may be clinically relevant. Cox proportional hazards modeling was performed using the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study database. 581 participants were followed for up to 12 years. Neurocognitive decline was defined as the first observed drop in global T-scores of at least 2.67. Lifetime methamphetamine use had the strongest association with neurocognitive decline (adjusted Hazard Ratio; aHR = 1.48; 95% CI = 0.92–2.39) followed by no current antiretroviral medication use (aHR = 1.32; 95% CI = 0.91–1.92). Other risk factors included Hispanic ethnicity, lifetime history of major depressive disorder, lifetime cannabis use, hepatitis-C infection, and difficulty eating, dressing, bathing, or using the toilet. Results indicate that consistent use of ART may be of high significance to preserving neurocognition. Furthermore, Hispanic patients, those with a history of depression and substance use, and those having difficulty in essential activities of daily living may require vigilant follow-up.
TrickeyAMayMTVehreschildJJ, et al.Survival of HIV–positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV2017; 4: e349–e356.
2.
De CockKMJaffeHWCurranJW. The evolving epidemiology of HIV/AIDS. AIDS2012; 26: 1205–1213.
3.
SaylorDDickensAMSacktorN, et al.HIV–associated neurocognitive disorder–pathogenesis and prospects for treatment. Nat Rev Neurol2016; 12: 234–248.
4.
ThamesADArentoftARivera-MindtM, et al.Functional disability in medication management and driving among individuals with HIV: A 1–year follow–up study. J Clin Exp Neuropsychol2013; 35: 49–58.
5.
MorganEEWoodsSPIudicelloJE, et al.Poor self–efficacy for healthcare provider interactions among individuals with HIV–ssociated neurocognitive disorders. J Clin Psychol Med Settings2019; 26: 13–24.
6.
MarquineMJFloresIKamatR, et al.A composite of multisystem injury and neurocognitive impairment in HIV infection: Association with everyday functioning. J Neurovirol2018; 24: 549–556.
7.
JonesJDKuhnTLevineA, et al.Changes in cognition precede changes in HRQoL among HIV + males: Longitudinal analysis of the multicenter AIDS cohort study. Neuropsychology2019; 33: 370–378.
8.
BanerjeeNMcIntoshRCIronsonG. Impaired neurocognitive performance and mortality in HIV: Assessing the prognostic value of the HIV–dementia scale. AIDS Behav2019; 23: 3482–3492.
9.
GrantIFranklinDRJrDeutschR, et al.Asymptomatic HIV–associated neurocognitive impairment increases risk for symptomatic decline. Neurology2014; 82: 2055–2062.
10.
McArthurJC. HIV dementia: An evolving disease. J Neuroimmunol2004; 157: 3–10.
11.
PaolilloEWPasipanodyaECMooreRC, et al.Cumulative burden of depression and neurocognitive decline among persons with HIV: A longitudinal study. J Acquir Immune Defic Syndr2020; 84: 304–312.
12.
PaolilloEWSun-SuslowNPasipanodyaEC, et al.Pre–frailty predicts cognitive decline at 2–year follow–up in persons living with HIV. J.Neurovirol2019; 26: 168–180.
13.
RubinLHGustafsonDHawkinsKL, et al.Midlife adiposity predicts cognitive decline in the prospective multicenter AIDS cohort study. Neurology2019; 93: e261–e271.
14.
HeatonRKFranklinDRJrDeutschR, et al.Neurocognitive change in the era of HIV combination antiretroviral therapy: The longitudinal CHARTER study. Clin Infect Dis2015; 60: 473–480.
15.
WoodsSPChildersMEllisRJ, et al.A battery approach for measuring neuropsychological change. Arch Clin Neuropsychol2006; 21: 83–89.
16.
DufourCAMarquineMJFazeliPL, et al.A longitudinal analysis of the impact of physical activity on neurocognitive functioning among HIV–infected adults. AIDS Behav2018; 22: 1562–1572.
17.
YuenTBrouilletteMJFellowsLK, et al.Personalized risk index for neurocognitive decline among people with well–controlled HIV infection. J Acquir Immune Defic Syndr2017; 76: 48–54.
18.
NormanGRSloanJAWyrwichKW. Interpretation of changes in health–related quality of life: The remarkable universality of half a standard deviation. Med Care2003; 41: 582–592.
HeatonRMillerSWTaylorMJ, et al.Revised comprehensive norms for an expanded Halstead–Reitan battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults. Lutz, FL: Psychological Assessment Resources, 2004.
21.
NormanMAMooreDJTaylorM, et al.Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol2011; 33: 793–804.
DiehrMCChernerM, et al.The 50 and 100-Item Short Forms of the Paced Auditory Serial Addition Task (PASAT): Demographically Corrected Norms and Comparisons with the Full PASAT in Normal and Clinical Samples. J Clin Exp Neuropsychol2003; 25: 571–585.
BenedictRHBSchretlenDGroningerL, et al.Hopkins Verbal Learning Test - Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. The Clin Neuropsychologist1998; 12: 43–55.
26.
HeatonRKCliffordDBFranklinDRJr, et al.HIV–associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology2010; 75: 2087–2096.
27.
CareyCLWoodsSPGonzalezR, et al.Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol2004; 26: 307–319.
28.
BlackstoneKMooreDJFranklinDR, et al.Defining neurocognitive impairment in HIV: Deficit scores versus clinical ratings. Clin Neuropsychol2012; 26: 894–908.
29.
AntinoriAArendtGBeckerJT, et al.Updated research nosology for HIV–associated neurocognitive disorders. Neurology2007; 69: 1789–1799.
30.
CysiqueLABrewBJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: A review. Neuropsychol Rev2009; 19: 169–185.
31.
CysiqueLAVaidaFLetendreS, et al.Dynamics of cognitive change in impaired HIV–positive patients initiating antiretroviral therapy. Neurology2009; 73: 342–348.
32.
HusstedtIWFrohneLBöckenholtS, et al.Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: Cross–sectional and longitudinal studies of event–related potentials. AIDS Res Hum Retroviruses2002; 18: 485–490.
33.
WrightEJGrundBRobertsonKR, et al.No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T–cell counts. AIDS2018; 32: 985–997.
34.
SacktorNNakasujjaNOkonkwoO, et al.Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda. J Neurovirol2013; 19: 48–56.
35.
FurtadoMKatzmanMA. Examining the role of neuroinflammation in major depression. Psychiatry Res2015; 229: 27–36.
36.
FortonDMAllsopJMMainJ, et al.Evidence for a cerebral effect of the hepatitis C virus. Lancet2001; 358: 38–39.
37.
CattieJELetendreSLWoodsSP, et al.Persistent neurocognitive decline in a clinic sample of hepatitis C virus–infected persons receiving interferon and ribavirin treatment. J Neurovirol2014; 20: 561–570.
38.
OettlKStauberRE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol2007; 151: 580–590.
39.
CiccarelliNFabbianiMGrimaP, et al.Comparison of cognitive performance in HIV or HCV mono–infected and HIV–HCV co–infected patients. Infection2013; 41: 1103–1109.
40.
JanssenMAMKoopmansPPKesselsRPC. Cognitive decline in relation to psychological wellbeing and HIV disease–and treatment characteristics in HIV–infected patients on cART: A one–year follow–up study. AIDS Behav2017; 21: 1728–1734.
41.
RippethJDHeatonRKCareyCL, et al.Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc2004; 10: 1–14.
42.
CastellanoPNwagboCMartinezLR, et al.Methamphetamine compromises gap junctional communication in strocytes and neurons. J Neurochem2016; 137: 561–575.
43.
CrookCLSavinMJByrdD, et al.The neurocognitive effects of a past cannabis use disorder in a diverse sample of people living with HIV. AIDS Care2020: 1–10.
44.
WatsonCWPaolilloEWMorganEE, et al.Cannabis exposure is associated with a lower likelihood of neurocognitive impairment in people living with HIV. J Acquir Immune Defic Syndr2020; 83: 56–64.
45.
OkaforCNPlankeyMWLiM, et al.Association of marijuana use with changes in cognitive processing speed and flexibility for 17 years in HIV–seropositive and HIV–seronegative men. Subst Use Misuse2019; 54: 525–537.
46.
DennisAMNapravnikSSeñaAC, et al.Late entry to HIV care among Latinos compared with non–Latinos in a Southeastern US cohort. Clin Infect Dis2011; 53: 480–487.
47.
ChenNEGallantJEPageKR. A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States. J Immigr Minor Health2012; 14: 65–81.
48.
LosinaESchackmanBRSadownikSN, et al.Racial and sex disparities in life expectancy losses among HIV–infected persons in the United States: Impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis2009; 49: 1570–1578.
49.
CysiqueLALetendreSLAkeC, et al.Incidence and nature of cognitive decline over 1 year among HIV–infected former plasma donors in China. AIDS2010; 24: 983–990.
50.
HeatonRKMarcotteTDMindtMR, et al.The impact of HIV–associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc2004; 10: 317–331.
